Your browser doesn't support javascript.
loading
Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease.
Domenighetti, Cloé; Sugier, Pierre-Emmanuel; Sreelatha, Ashwin Ashok Kumar; Schulte, Claudia; Grover, Sandeep; Mohamed, Océane; Portugal, Berta; May, Patrick; Bobbili, Dheeraj R; Radivojkov-Blagojevic, Milena; Lichtner, Peter; Singleton, Andrew B; Hernandez, Dena G; Edsall, Connor; Mellick, George D; Zimprich, Alexander; Pirker, Walter; Rogaeva, Ekaterina; Lang, Anthony E; Koks, Sulev; Taba, Pille; Lesage, Suzanne; Brice, Alexis; Corvol, Jean-Christophe; Chartier-Harlin, Marie-Christine; Mutez, Eugénie; Brockmann, Kathrin; Deutschländer, Angela B; Hadjigeorgiou, Georges M; Dardiotis, Efthimos; Stefanis, Leonidas; Simitsi, Athina Maria; Valente, Enza Maria; Petrucci, Simona; Duga, Stefano; Straniero, Letizia; Zecchinelli, Anna; Pezzoli, Gianni; Brighina, Laura; Ferrarese, Carlo; Annesi, Grazia; Quattrone, Andrea; Gagliardi, Monica; Matsuo, Hirotaka; Kawamura, Yusuke; Hattori, Nobutaka; Nishioka, Kenya; Chung, Sun Ju; Kim, Yun Joong; Kolber, Pierre.
Affiliation
  • Domenighetti C; Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.
  • Sugier PE; Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.
  • Sreelatha AAK; Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany.
  • Schulte C; Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany.
  • Grover S; German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany.
  • Mohamed O; Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany.
  • Portugal B; Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.
  • May P; Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.
  • Bobbili DR; Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.
  • Radivojkov-Blagojevic M; Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.
  • Lichtner P; MeGeno S.A, Esch-sur-Alzette, Luxembourg.
  • Singleton AB; Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.
  • Hernandez DG; Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.
  • Edsall C; Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA.
  • Mellick GD; Center For Alzheimer's and Related Dementias, NIA, NIH, Bethesda, MD, USA.
  • Zimprich A; Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA.
  • Pirker W; Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA.
  • Rogaeva E; Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, Queensland, Australia.
  • Lang AE; Department of Neurology, Medical University of Vienna, Austria.
  • Koks S; Department of Neurology, Wilhelminenspital, Austria.
  • Taba P; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
  • Lesage S; Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada.
  • Brice A; Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
  • Corvol JC; Krembil Brain Institute, Toronto, Ontario, Canada.
  • Chartier-Harlin MC; Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia.
  • Mutez E; Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia.
  • Brockmann K; Department of Neurology and Neurosurgery, University of Tartu, Estonia.
  • Deutschländer AB; Neurology Clinic, Tartu University Hospital, Tartu, Estonia.
  • Hadjigeorgiou GM; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France.
  • Dardiotis E; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France.
  • Stefanis L; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France.
  • Simitsi AM; Assistance Publique Hôpitaux de Paris, Department of Neurology, CIC Neurosciences, Paris, France.
  • Valente EM; Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - LilNCog- Centre de Recherche Lille Neurosciences & Cognition, Lille, France.
  • Petrucci S; Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - LilNCog- Centre de Recherche Lille Neurosciences & Cognition, Lille, France.
  • Duga S; Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany.
  • Straniero L; German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany.
  • Zecchinelli A; Department of Neurology, Ludwig Maximilians University of Munich, Germany.
  • Pezzoli G; Department of Neurology, Max Planck Institute of Psychiatry, Munich, Germany.
  • Brighina L; Department of Neurology and Department of Clinical Genomics, Mayo Clinic Florida, Jacksonville, FL, USA.
  • Ferrarese C; Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece.
  • Annesi G; Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus.
  • Quattrone A; Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece.
  • Gagliardi M; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Matsuo H; Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
  • Kawamura Y; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Hattori N; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Nishioka K; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy.
  • Chung SJ; UOC Medical Genetics and Advanced Cell Diagnostics, S. Andrea University Hospital, Rome, Italy.
  • Kim YJ; Department of Clinical and Molecular Medicine, University of Rome, Rome, Italy.
  • Kolber P; Department of Biomedical Sciences - Humanitas University, Milan, Italy.
J Parkinsons Dis ; 12(1): 267-282, 2022.
Article in En | MEDLINE | ID: mdl-34633332
ABSTRACT

BACKGROUND:

Previous studies showed that lifestyle behaviors (cigarette smoking, alcohol, coffee) are inversely associated with Parkinson's disease (PD). The prodromal phase of PD raises the possibility that these associations may be explained by reverse causation.

OBJECTIVE:

To examine associations of lifestyle behaviors with PD using two-sample Mendelian randomisation (MR) and the potential for survival and incidence-prevalence biases.

METHODS:

We used summary statistics from publicly available studies to estimate the association of genetic polymorphisms with lifestyle behaviors, and from Courage-PD (7,369 cases, 7,018 controls; European ancestry) to estimate the association of these variants with PD. We used the inverse-variance weighted method to compute odds ratios (ORIVW) of PD and 95%confidence intervals (CI). Significance was determined using a Bonferroni-corrected significance threshold (p = 0.017).

RESULTS:

We found a significant inverse association between smoking initiation and PD (ORIVW per 1-SD increase in the prevalence of ever smoking = 0.74, 95%CI = 0.60-0.93, p = 0.009) without significant directional pleiotropy. Associations in participants ≤67 years old and cases with disease duration ≤7 years were of a similar size. No significant associations were observed for alcohol and coffee drinking. In reverse MR, genetic liability toward PD was not associated with smoking or coffee drinking but was positively associated with alcohol drinking.

CONCLUSION:

Our findings are in favor of an inverse association between smoking and PD that is not explained by reverse causation, confounding, and survival or incidence-prevalence biases. Genetic liability toward PD was positively associated with alcohol drinking. Conclusions on the association of alcohol and coffee drinking with PD are hampered by insufficient statistical power.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Parkinson Disease / Coffee Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Language: En Journal: J Parkinsons Dis Year: 2022 Type: Article Affiliation country: France

Full text: 1 Database: MEDLINE Main subject: Parkinson Disease / Coffee Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Language: En Journal: J Parkinsons Dis Year: 2022 Type: Article Affiliation country: France